456 results about "Pelvic inflammatory disease" patented technology

Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

There is disclosed a method for treating dermatologic diseases caused by microbial overgrowth or inflammation, such as psoriasis, fungal infections, eczema, dandruff, acne, genital herpes lesions, and leg ulcers. There is further disclosed an antiviral lubricating composition that is effective in preventing the transmission of the HIV virus and other sexually transmitted diseases. There is also disclosed systemic and anti-inflammatory compositions and formulations and a method for reducing tissue inflammation in tissues such as the bowel, muscle, bone, tendon and joints (e.g., arthritis).

The invention features compositions and methods for treating or preventing a neoplasia. More specifically, the invention provides compositions and methods for disrupting the interaction of a BET family polypeptide comprising a bromodomain with chromatin (e.g., disrupting a bromodomain interaction with an acetyl-lysine modification present on a histone N-terminal tail).

This invention is directed to methods of preventing or treating diseases or conditions associated with excessive cell proliferation, remodeling, edema and inflammation. Particularly, this invention is directed to methods of treating inflammatory diseases or conditions such as rheumatoid arthritis and inflammatory bowel disease. The method comprises identifying a subject in need of the treatment, and administering to the subject an effective amount of a compound of a novel rho kinase inhibitor compound to treat the disease.

A strain of Bifidobacterium isolated from resected and washed human gastrointestinal tract is significantly immunomodulatory following oral consumption in humans. The strain is useful in the prophylaxis and/or treatment of undesirable inflammatroy activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer.

The invention discloses a medicinal composition for treating gynecological inflammation, and belongs to the field of Chinese medicament. The medicinal composition consists of collagen and/or Chinese medicaments for releasing toxin and sterilizing such as collagen and lizardtail, glabrous greenbrier rhizome, Vietnamese sophora root and the like which are prepared into a plurality of dosage forms bycombining the prior art, and is mainly used for treating vaginitis, pelvic inflammation, urethritis and cervicitis diseases. The technical scheme overcomes the defects that the prior externally-applied preparations such as lotion, gel, suppository, ointment and the like have extremely slow response, longer disease course, repeated outbreak and the like, and creatively combines and applies the collagen and the Chinese medicament, can accelerate the healing of ulcer and erosion faces caused by the inflammation, and can greatly shorten the required time for tissue repair.

The present invention provides novel methods of treatment of multiple sclerosis and other autoimmune diseases or inflammatory disorders, and antagonists, including isolated binding proteins for use in the novel methods. There is provided a method of treating multiple sclerosis comprising the neutralization of the biological activity of IL-7 by binding to CD127 or IL-7. The isolated binding proteins may also neutralize the biological activity of TSLP.

The invention discloses a Chinese traditional medicine compound preparation for treating gynecopathy and preparation method, wherein the preparation comprises the active compositions including flavescent sophora root, elephantopus, Chinese angelica root, spatholobus stem, shiny pricklyash, persimmon leaf, Herba thlaspis and wild peach.

The present invention provides a novel agent for prophylaxis or treatment of inflammatory bowel diseases for oral administration or intra-intestinal infusion, which comprises as an active ingredient a compound of the formula (I):or a pharmaceutically acceptable salt thereof; a use of said active ingredient in preparation of an agent for prophylaxis or treatment of inflammatory bowel diseases; and a method for prophylaxis or treatment of inflammatory bowel diseases.

The present invention relates to the use of fragments of heat shock proteins for the treatment and/or prevention of autoimmune diseases such as arthritis or inflammatory diseases such as Inflammatory Bowel Diseases. Preferably bacterial and/or mammalian heat shock proteins belonging to the HSP70 families are used.

The invention relates to an oral spray for inflammatory diseases of the oral cavity and a preparation method thereof. The oral spray comprises the following components: 0.1-5% of water-soluble chitosan, 0.5-5% of propolis extract, 0.1-1% of lactoferrin, 0.01-0.5% of lactoperoxidase, 0.1-0.5% of lysozyme, 0.01-0.1% of immunoglobulin, 1-10% of bovine colostrum extract, 1-10% of anti-caries sweetener, 0.8-1.2% of cold aromatic, 0.1-1% of preservative and the balance of water for injections. The preparation method is characterized by mixing the components, stirring uniformly, filling into an oral sprayer, and sterilizing at 85 DEG C for 15 minutes to obtain the finished product. The oral spray has the effect of immediately and rapidly treating inflammatory diseases of the oral cavity and the functions of resisting bacteria and viruses, relieving pains, reducing gum inflammation and blooding, promoting the healing of oral ulcer wounds, treating acute and chronic pharyngitis, moistening and freshening the oral cavity and removing halitosis. The oral spray has the advantages of simple and convenient large-scale production process and no environmental pollution in the production process.

A method and system of reducing the likelihood of an inflammatory disease developing by providing a mucosal adhesive strip to a subject, with the strip provided with at least one of a plurality of agents effective to hinder the growth of spirochetes bacteria in a subject's oral cavity. In certain embodiments, an effective amount of Prevotella intermedia is provided to decrease the incidence of periodontitis and to reduce the progression of Alzheimer's disease. In still other embodiments, the likelihood that a subject will suffer from Alzheimer's disease is reduced by administering via local gingival application to a subject that has been diagnosed with periodontitis an effective amount of an antibiotic effective to kill spirochetes bacteria residing on the subgingival tooth area of the subject.

The invention provides an acupoint stimulator and an acupoint stimulation system. At least one electrode is in contact with acupoints of a user, and any alternating current in a range of 3-35 mA is output to stimulate the acupoints of the human body. The scheme has the following advantages that a very good treatment or health care effect is achieved on various chronic diseases including endocrinedisorders, inflammatory diseases and nervous system disorder diseases which cannot be cured by any method currently. A traditional Chinese medicine syndrome differentiation method is adopted, individual difference traits are fully considered, and the overall diagnosis and treatment based on syndrome differentiation are conducted by objectively measuring meridian and collateral data of the user; the maximum predicted safe current is used for providing the most effective treatment for patients.

The present invention relates to compositions and methods for diagnosing, monitoring and/or treating disease (e.g., autoimmune or chronic inflammatory disease, heart disease and/or stroke). In particular, the present invention provides methods for diagnosing, monitoring and treating disease based upon detecting or altering (e.g., altering expression or methylation status of) disease proteins (e.g., CD70, CD40L, and/or KIR). The present invention also provides kits for detecting methylation status of disease proteins (e.g., CD70, CD40L, and/or KIR) and for diagnosing, monitoring and/or treating diseases (e.g., autoimmune or chronic inflammatory disease, heart disease and/or stroke).

A method for treating autoimmune and/or inflammatory diseases includes a step of identifying a subject having a gastrointestinal autoimmune/inflammatory disease. A fasting mimicking diet (FMD) is administered to the subject for a first time period.

The invention discloses a traditional Chinese medicine preparation for treating chronic pelvic inflammatory of women and a preparation method thereof. A medicine for oral administration comprises 10 to 20 portions of Salvia miltiorrhiza, 10 to 20 portions of radix astragali, 10 to 20 portions of sargentgloryvine stem, 10 to 20 portions of angelica, 10 to 20 portions of peach kernel, 10 to 20 portions of Field pennycress, 10 to 20 portions of Caulis Spatholobi, 10 to 20 portions of red peony root, 5 to 15 portions of trumpet creeper, 10 to 20 portions of yam, 5 to 10 portions of Chinese wolfberry, and 10 to 20 portions of date; and a medicine for external application comprises 10 to 30 portions of jinhuang powder, 10 to 30 portions of lopseed, 10 to 30 portions of honeysuckle, 10 to 30 portions of Caulis Spatholobi, 10 to 30 portions of fructus kochiae, 10 to 30 portions of natural indigo, 10 to 30 portions of frutus cnidii, 10 to 30 portions of Field pennycress, 10 to 30 portions of rose mallow herb, 10 to 20 portions of dandelion, and 10 to 30 portions of trumpet creeper. The traditional Chinese medicine preparation promotes blood circulation and removes blood stasis, regulates the menstrual function and nourishes blood, has a simple production method, and can obtain good economical benefit.

The invention discloses a new use of notoginsenoside R1 in the preparation of medicines for preventing and/or treating the inflammatory diseases of the digestive system or healthcare foods as an active component. Experiment results show that the notoginsenoside R1 has an inhibition effect on the NF-kappa B signal pathway, and has substantial prevention and treatment effects on the NF-kappa B signal pathway mediated ulcerative colonitis, so the notoginsenoside R1 can be developed to medicines for preventing and/or treating the inflammatory diseases of the digestive system or healthcare foods. The new use urges the notoginsenoside R1 to fully perform its medicinal values, and is very important for researching and applying Panax Notoginseng.

The invention relates to a granule used for treating chronic pelvic inflammatory disease. The granular formulation is characterized by being prepared from the following components in parts by weight: 1-75 parts of honeysuckle, 5-65 parts of red peony root, 3-50 parts of scutellaria baicalensis or golden cypress, 8-30 parts of sanguisorba or cacumen biotae, 5-20 parts of radix bupleuri, 1-40 partsof corydalis tuber or the rhizome of szechuan lovage rhizome, 2-40 parts of rhizoma cyperi or Chinese angelica and the root of three-nerved spicebush, 2-25 parts of semen coicis and 1-20 parts of rhizoma dioscoreae nipponicae. On the basis of 'dampness, heat, stagnation and obstruction', the granule is applied according to indications and has obvious treatment effect on pelvic inflammatory disease; and Chinese herbal medicines in the formula are available, the cost is relatively low, and the medicine is convenient to prepare by mass production.

The invention discloses a probiotics composition for alleviating or improving pelvic inflammatory diseases. The probiotics composition is prepared from lactobacillus rhamnosus, lactobacillus acidophilus and lactobacillus plantarum. In the probiotics composition, the total quantity of the probiotics is 8.0*10<9> to 4.0*10<10> cfu/g. The probiotics composition is synergistically combined with medicinal and herbal Chinese herbs to prepare a probiotics Chinese herbal preparation. Further, the probiotics composition, the medicinal and edible Chinese herb extract, prebiotics and the like are compounded to prepare a product for alleviating or improving the pelvic inflammatory diseases. The probiotics composition can improve the immunity of the body, can promote the development of physiologic normal probiotics group in genital tract can be promoted; and by virtue of bological antagonism, pathogenic bacteria is indirectly controlled and killed to adjust a micro-ecological balance in the genital tract, so that the pelvic inflammatory diseases are alleviated or improved.

The invention discloses an oral administration pharmaceutical composition for treating chronic pelvic inflammatory disease, wherein the active constituents include the following raw material herbs (by weight portion): honeysuckle flower 20g, capsule of weeping forsythia 10g, spatholobus stem 10g, herba patriniae 10g, coix seed 10g, red peony root 2g, peach kernel 12g, corydalis tuber 9g, toosendan fruit 9g, frankincense 4. 5g, myrrh 4. 5g, rhizome of Sichuan lovage 6g, motherwort 10g, flavescent sophora root 10g. The medicament should be decocted in water for the oral dose.

The invention relates to a method for preparing a new gynecological anti-bacterial anti-inflammatory drug, namely dithiazole vaginal effervescent tablet and a method for quality control. The dithiazole vaginal effervescent tablet is used for treating gynecopathy, anorectal diseases and skin commonly-encountered diseases such as pelvic inflammatory disease, cervical erosion, vaginitis and the like caused by anaerobic bacteria, aerobic bacteria, trichomoniasis, pure or mixed fungal infections. The dithiazole vaginal effervescent tablet is characterized in that lactic acid and a calcium lactate buffer system are added to the formulation so that the pH value of the drug is between 3.5 and 4.0 similar to the vaginal physiological pH and is advantageous to remove pathogen and infusorian, provide living conditions suitable for vaginal beneficial bacterium group of lactic acid bacteria, and promote the illness rehabilitation. Besides, the dithiazole vaginal effervescent tablet uses pharmaceutical acceptable water-soluble polymer materials such as water-soluble polymer polyethylene glycol, polyvidone K30 and the like to enwrap acidic or alkaline components of an effervescent disintegrant so as to avoid the occurrence of hidden spots or even collapsing phenomenon on the surface of the tablet caused by gas production reaction resulted from small amount of water in the storage process, and uses a ethanol solution with adhesives and surface-active agents for granulation so that the hydrolysis of clotrimazole can be prevented, the infiltration of moisture is promoted in use, the uniform collapse is accelerated, and gas bubbles are homogeneous and stable.